Key Considerations for the Management of RSV in Adult Patients
EP. 1: Overview of RSV Patient Populations
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD A panel of experts on respiratory syncytial virus (RSV) introduce themselves and give an overview of patients who are most affected by RSV.
EP. 2: Complications Associated with RSV Infections
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD Marty J. Feltner, PharmD, provides insights on complications associated with RSV infections and how complications vary for different patient populations.
EP. 3: The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD Focusing on the economic burden of RSV, the panel discusses financial considerations for multiple patient populations, highlighting hospitalization costs and the main drivers of healthcare resource utilization.
EP. 4: RSV: Risk Factors and How It’s Spread
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD A panel of experts outline who’s at risk for RSV and how it’s spread, highlighting how transmission can be minimized.
EP. 5: Diagnostic Practices for RSV
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD Focusing on the diagnosis of RSV, Mary Bridgeman, PharmD, BCPS, BCGP, provides clinical insights on signs and symptoms and testing practices.
EP. 6: Increasing Awareness of RSV Vaccines in At-Risk Patients
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD The expert panel discusses ways to increase awareness of the RSV vaccine for patients who would benefit from it.
EP. 7: Shared Decision-Making Practices in RSV
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD Experts on RSV vaccination discuss shared decision-making practices and the importance of getting at-risk patients vaccinated.
EP. 8: Financial and Clinical Benefits of RSV Immunization
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD Following the recent approval of RSV vaccines, the panel discusses the financial and clinical benefits, highlighting the fiscal impact seen in hospitals and ICUs.
EP. 9: The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD As phase 3 data for the RSV vaccine are leading the FDA to consider expanding the age range to include patients aged 50-59, the panel discusses the potential clinical and economic benefits.
EP. 10: Addressing Vaccine Fatigue
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD Mary Bridgeman, PharmD, BCPS, BCGP, discusses how providers and healthcare workers can address vaccine fatigue in patients eligible for the RSV vaccine.
EP. 11: Identifying Patients Eligible for RSV Vaccine
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD Experts from clinical and payer backgrounds discuss how patients eligible for the RSV vaccine can be identified.
EP. 12: Current and Potential Obstacles Related to Administering RSV Vaccines
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD An internal medicine pharmacist discusses current and potential obstacles related to administering RSV vaccines to patients from different age groups.
EP. 13: Improving Insurance Coverage for RSV Vaccines
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD The panel discusses what’s needed for payers to activate early coverage for RSV vaccines in adults and how coverage has been since the approval of the 2 RSV vaccines.
EP. 14: Improving RSV Vaccination Rates and Addressing Misinformation
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD Experts on RSV provide insights on improving RSV vaccination rates, highlighting ways to navigate misinformation.
EP. 15: Key Takeaways on RSV Vaccination
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD The panel concludes its discussion by providing key takeaways on the evolving RSV vaccination landscape.
